Kiora Total Liabilities vs Price to Earnings Ratio Analysis
KPRX Stock | USD 0.51 0.07 12.07% |
Trend analysis of Kiora Pharmaceuticals balance sheet accounts such as Total Current Liabilities of 3.2 M provides information on Kiora Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Kiora Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Kiora Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Kiora |
About Kiora Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Kiora Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Kiora Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Kiora Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Kiora currently owns. An asset can also be divided into two categories, current and non-current.
Kiora Pharmaceuticals Balance Sheet Chart
Kiora Pharmaceuticals Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Kiora Pharmaceuticals uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, Kiora Pharmaceuticals' Common Stock is fairly stable compared to the past year. Current Deferred Revenue is likely to rise to about 4.9 M in 2024, whereas Total Assets are likely to drop slightly above 11.7 M in 2024. Add Fundamental
Total Assets
Total assets refers to the total amount of Kiora Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Kiora Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Kiora Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Kiora Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from Kiora Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Kiora Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiora Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide.At this time, Kiora Pharmaceuticals' Tax Provision is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 8.7 M in 2024, whereas Selling General Administrative is likely to drop 4,430 in 2024.
Kiora Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Kiora Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Kiora Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 10.1M | 15.2M | 18.1M | 18.7M | 13.7M | 11.7M | |
Short Long Term Debt Total | 83.9K | 362.1K | 209.4K | 105.8K | 106.9K | 101.5K | |
Other Current Liab | 1.1M | 1.3M | 1.3M | 2.2M | 1.4M | 1.3M | |
Total Current Liabilities | 1.4M | 1.8M | 1.6M | 3.3M | 1.6M | 3.2M | |
Total Stockholder Equity | 6.6M | 7.0M | 9.2M | 11.4M | 6.1M | 6.4M | |
Property Plant And Equipment Net | 16.8K | 30.6K | 283.4K | 172.2K | 115.0K | 76.8K | |
Net Debt | (3.7M) | (823.6K) | (7.6M) | (5.9M) | (2.3M) | (2.5M) | |
Retained Earnings | (100.2M) | (108.3M) | (124.7M) | (134.5M) | (147.0M) | (154.3M) | |
Accounts Payable | 210.3K | 434.8K | 160.6K | 1.0M | 206.3K | 195.9K | |
Cash | 3.8M | 1.2M | 7.9M | 6.0M | 2.5M | 4.7M | |
Non Current Assets Total | 5.8M | 13.3M | 9.1M | 11.0M | 9.0M | 6.1M | |
Non Currrent Assets Other | 114.4K | 102.1K | 88.0K | 82.3K | 40.8K | 38.7K | |
Cash And Short Term Investments | 3.8M | 1.2M | 7.9M | 6.0M | 2.5M | 4.7M | |
Net Receivables | 4.9K | 91.0K | 529.6K | 1.4M | 2.0M | 2.2M | |
Common Stock Shares Outstanding | 79.5K | 114.8K | 241.1K | 732.3K | 4.8M | 5.1M | |
Liabilities And Stockholders Equity | 10.1M | 15.2M | 18.1M | 18.7M | 13.7M | 11.7M | |
Non Current Liabilities Total | 2.1M | 6.4M | 7.2M | 4.0M | 6.0M | 10.2M | |
Other Current Assets | 542.7K | 533.5K | 606.5K | 343.1K | 233.4K | 368.7K | |
Other Stockholder Equity | 106.7M | 115.3M | 133.9M | 146.0M | 153.2M | 93.1M | |
Total Liab | 3.5M | 8.2M | 8.8M | 7.3M | 7.6M | 12.5M | |
Total Current Assets | 4.3M | 1.8M | 9.0M | 7.7M | 4.7M | 5.6M | |
Accumulated Other Comprehensive Income | 139.5K | (802.0) | (86.4K) | (182.7K) | (182.8K) | (173.7K) | |
Short Term Debt | 83.9K | 48.3K | 118.8K | 105.8K | 47.1K | 44.7K | |
Common Stock | 40.8K | 55.6K | 126.6K | 18.0K | 77.1K | 101.9K | |
Intangible Assets | 4.1M | 9.7M | 8.7M | 10.7M | 8.8M | 7.9M | |
Other Liab | 1.5M | 2.1M | 6.1M | 7.1M | 8.2M | 8.6M | |
Net Tangible Assets | 7.2M | 4.9M | 3.3M | 9.1M | 10.4M | 10.9M | |
Capital Lease Obligations | 83.9K | 83.9K | 209.4K | 105.8K | 106.9K | 96.0K | |
Net Invested Capital | 6.6M | 7.3M | 9.2M | 11.4M | 6.1M | 7.5M | |
Non Current Liabilities Other | 1.7M | 5.3M | 6.5M | 3.3M | 5.1M | 3.8M | |
Net Working Capital | 2.9M | 37.8K | 7.4M | 4.4M | 3.1M | 2.5M | |
Property Plant Equipment | 43.5K | 16.8K | 30.6K | 283.4K | 325.9K | 342.2K | |
Capital Stock | 40.8K | 55.6K | 126.6K | 18.0K | 77.1K | 100.8K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiora Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Complementary Tools for Kiora Stock analysis
When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Kiora Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiora Pharmaceuticals. If investors know Kiora will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiora Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.69) | Revenue Per Share 0.002 | Return On Assets (0.34) | Return On Equity (1.43) |
The market value of Kiora Pharmaceuticals is measured differently than its book value, which is the value of Kiora that is recorded on the company's balance sheet. Investors also form their own opinion of Kiora Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kiora Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiora Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kiora Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kiora Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kiora Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiora Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.